EGFR and neoplasm: XL765 in combination with erlotinib is also generally well tolerated at daily doses up to 50 mg XL765/100 mg erlotinib with no apparent pharmacokinetic interaction, and results in robust inhibition of PI3K and EGFR signalling in skin and tumour tissue.